Foxa2 has been proposed as a mesenchymal-to-epithelial transition (MET) driver in murine loss-of-function studies (Burtscher and Lickert, 2009) and in various human cancers (Myatt and Lam, 2007). This evidence concerns the gene FOXA2 and cancer.